Modified erythropoietin (EPO) with reduced immunogenicity

本发明涉及尤其是用于对人施用的、特别是用于治疗的多肽。所述的多肽是经修饰的多肽，其中，所述的修饰使得上述多肽在施用于人体时引起免疫应答的倾向减弱。本发明特别涉及对促红细胞生成素(EPO)进行修饰以产生促红细胞生成素蛋白，该蛋白在体内使用时基本上无免疫原性，或比未经修饰的相应蛋白的免疫原性低。 The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modifie...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	F.J. CARR, G. CARTER, T. JONES
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	BEER BIOCHEMISTRY CALCULATING CHEMISTRY COMPOSITIONS THEREOF COMPUTING COUNTING CULTURE MEDIA ELECTRIC DIGITAL DATA PROCESSING ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTEDFOR SPECIFIC APPLICATION FIELDS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	本发明涉及尤其是用于对人施用的、特别是用于治疗的多肽。所述的多肽是经修饰的多肽，其中，所述的修饰使得上述多肽在施用于人体时引起免疫应答的倾向减弱。本发明特别涉及对促红细胞生成素(EPO)进行修饰以产生促红细胞生成素蛋白，该蛋白在体内使用时基本上无免疫原性，或比未经修饰的相应蛋白的免疫原性低。 The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The inention in particular relates to the modification of erythropoietin (EPO) to result in erythropoietin proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.